VIDEO: CAR T-cell therapies for multiple myeloma ‘have come a long way'

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So, [chimeric antigen receptor (CAR)] T-cell therapies in multiple myeloma have come a long way in the past 6 years. We’ve gone from seeing the early clinical data in the relapse/refractory setting with patients who’ve had four or more prior lines of treatment, to getting those therapies approved. We have two products, [idecabtagene vicleucel, or ide-cel (Abecma; Bristol Myers Squibb, 2seventy bio)] and [ciltacabtagene autoleucel, or cilta-cel (Carvykti; Janssen, Legend Biotech)], that are commercially available for that late relapsed setting. More recently, we’ve seen clinical trial data with both ide-cel and cilta-cel in early-relapse setting. For ide-cel, we have the KarMMa-3 trial that looked at two to four prior lines of treatment setting, compared to standard of care. And for cilta-cel, we had CARTITUDE-4 readout in one to three prior lines of treatment with cilta-cel, compared to standard of care — both trials reading out positively, in terms of the progression-free survival as primary endpoint. And so, we are really waiting on the potential regulatory approval of both these products in earlier lines of treatment.